Calcium Channel Blockers and Limitation of Myocardial Infarction Size

  • Zoltan G. Turi
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 41)

Abstract

Initial great enthusiasm for the use of calcium channel blocking agents in acute myocardial infarction (AMI) stems from the work of Oliva (1) in which 40% of patients catheterized immediately after onset of symptoms could be demonstrated to have restoration of flow through a previously occluded coronary vessel following the selective intracoronary injection of nitroglycerin. These findings coincided with those of Maseri (2) that some patients with reversible coronary vasospasm would eventually develop myocardial infarction in the same vascular distribution. Thus, drugs with potent coronary spasmolytic effect, such as calcium channel blocking agents, might be highly effective in restoring flow to infarcting areas of myocardium.

Keywords

Placebo Depression Ischemia Carbohydrate Cardiol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Oliva PB, Breckinridge JC: Arteriography evidence of coronary arterial spasm in acute myocardial infarction. Circulation (56): 366–374, 1977.PubMedGoogle Scholar
  2. 2.
    Maseri A, L’Abbate A, Baroldi G, Chierchia S, Marzilli M, Ballestra AM, Severi S, Parodi O, Biagini A, Distante A, Pesola A: Coronary vasospasm as a possible cause of myocardial infarction: A conclusion derived from the study of “preinfarction” angina. New Engl J Med (299): 1271–1277, 1978.Google Scholar
  3. 3.
    Ganz W, Buchbinder N, Marcus H, Mondkar A, Maddahi J, Charuzi Y, O’Connor L, Shell W, Fishbein MC, Kass R, Mujamoto A, Swan HJC: Intracoronary thrombolysis in evolving myocardial infarction. Am Heart J (101): 4–13, 1981.CrossRefGoogle Scholar
  4. 4.
    Stone PH:Use of calcium channel blocking agents to salvage ischemic myocardium. In: Hoffman BF, ed. Calcium antagonists: The state of the art and role in cardiovascular disease. Symposia on Fromtiers of Pharmacology (2): 209–223, 1983.Google Scholar
  5. 5.
    Fleckenstein A: Specific inhibitors and promoters of calcium action in the excitation contraction coupling of heart muscle and their role in the prevention of production of myocardial lesions. In: Harris P, Opie L, eds. Calcium and the heart. Academic Press, New York, 1971, pp 135–188.Google Scholar
  6. 6.
    Clark RE, Christlieb IY, Henry PD, Fischer AE, Nora JD, Williamson JR, Sobel BE: Nifedipine: A myocardial protective agent. Am J Cardiol (44): 825–831, 1979.CrossRefGoogle Scholar
  7. 7.
    Verdouw PD, Ten-Cate FJ, Hartog M, Scheffer MG, Stam H: Intracoronary infusion of small doses of nifedipine lowers regional myocardial O2-consumption without altering regional myocardial function. Basic Res Cardiol (77): 26–33, 1982.CrossRefGoogle Scholar
  8. 8.
    Brooks WW, Verrier RL, Lown B: Protective effect of verapamil on vulnerability to ventricular fibrillation during myocardial ischaemia and reperfusion. Cardiovase Res (l4): 295–302, 1980.Google Scholar
  9. 9.
    Henry PD, Shuchleib R, Borda LJ, Roberts R, Williamson JR, Sobel BE: Effects of nifedipine on myocardial perfusion and ischemic injury in dogs. Circ Res (43): 372–380, 1978.Google Scholar
  10. 10.
    DeBoer LWV, Strauss HW, Kloner RA, Rude RE, Davis RF, Maroko PR, Braunwald E: Autoradiographic method of measuring the ischemic myocardium at risk: effects of verapamil on infarct size after experimental coronary artery occlusion. Proc Natl Acad Sci USA (77): 6119–6123, 1980.CrossRefGoogle Scholar
  11. 11.
    Nakamura M, Kajwaya Y, Yamada A, et al: Effects of diltiazem, a new antianginal drug on myocardial blood flow following experimental coronary occlusion. In: Winbury MM, Abiko Y, eds. Ischemic Myocardium and Anti-anginal Drugs. Raven Press, New York, 1979, pp 129–142.Google Scholar
  12. 12.
    Selwyn AP, Welman E, Fox K, Harlock P, Pratt T, Klein M: The effects of nifedipine on acute experimental myocardial ischemia and infarction in dogs. Circ Res (44): 16–23, 1979.Google Scholar
  13. 13.
    Bussmann WD, Schofer H, Kaltenbach M: Die hamodynamische Wirkung von Nifedipine bei akutem Herzinfarkt. Herz/Kreislauf (9)(3): 140–147, 1977.Google Scholar
  14. 14.
    Deaisieux J-C, et al: Hemodynamic effects of a single oral dose of nifedipine following acute myocardial infarction. Chest (78): 574, 1980.Google Scholar
  15. 15.
    Roberts R, Jaffe AS, Henry PD, Sobel BE: Nifedipine and acute myocardial infarction. Herz (6): 90–97, 1981.Google Scholar
  16. 16.
    Bussman WD, Seher W, Grungras M, Klepzig H: Reduktioin der Ck-und CKMB- Infarktgrosse durch intravenose Gabe von Verapamil. Zeitschrift fur Kardiologie (71): 164, 1982.Google Scholar
  17. 17.
    Muller J, Morrison J, Stone P, Rude R, Rosner B, Roberts R, Pearle D, Turi Z, Schneider J, Serfas D, Hennekens C, Braunwald E: Nifedipine therapy for threatened and acute myocardial infarction: A randomized double blind comparison. Circulation (68)(SuppIII): III–120, 1983.Google Scholar
  18. 18.
    Danish Multicenter Group. Verapamil in acute myocardial infarction. Clin Exp Pharm Physiol (6): 89, 1982.Google Scholar
  19. 19.
    Hillis LD, Fishbein MC, Braunwald E, Maroko PR: The influence of the time interval between coronary artery occlusion and the administration of hyaluronidase on salvage of ischemic myocardium in dogs. Circ Res (41): 26–31, 1977.Google Scholar
  20. 20.
    Miura M, Thomas R, Ganz W, Sokol T, Shell WE, Toshimitsu T, Kwan AC, Singh BN: The effect of delay in propranolol administration on reduction of myocardial infarct size after experimental coronary artery occlusion in dogs. Circulation (59): 1148–1157, 1979.Google Scholar
  21. 21.
    Reduto LA, Freund GC, Gaeta JM: Coronary artery reperfusion in acute myocardial infarction: Beneficial effects of intracoronary streptokinase on left ventricular salvage and performance. Am Heart J (102): 1168, 1981.Google Scholar
  22. 22.
    Muller J, Roberts R, Stone P, Rude R, Raabe D, Gold H, Jaffe A, Strauss W, Turi Z, Hart well T, Poole K, Passamani E, Willerson J, Sobel B, Braunwald E, and MILIS Group:Failure of propranolol administration to limit infarct size in patients with acute myocardial infarction. Circulation (68) (Suppl III): III–294, 1983.Google Scholar
  23. 23.
    Yusuf S, Sleight P, Rossi P, Ramsdale D, Peto R, Furze L, Sterry H, Pearson M, Motwani R, Parish S, Gray R, Bennett D, Bray C: Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation (67)(Supp l):I–32–I–41, 1983.Google Scholar
  24. 24.
    Peter T, Norris RM, Clarke ED, Heng MK, Singh BN, Williams B, Howell DR, Ambler PK: Reduction of Enzyme Levels by Propranolol After Acute Myocardial Infarction. Circulation (57): 1091–1095, 1978.Google Scholar
  25. 25.
    Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Eng J Med (304): 801, 1981.Google Scholar
  26. 26.
    ß-Blocker Heart Attack Trial Research Group: A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA (2 47 ): 1707–1714.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • Zoltan G. Turi

There are no affiliations available

Personalised recommendations